Key result
In patients with AF and VHD, dabigatran 150 mg reduced the risk of stroke compared to warfarin (RR 0.59; 95% CI 0.36-0.98), and multiple DOACs significantly lowered the risk of intracranial hemorrhage.
Why the study?
The safety and efficacy of DOACs compared with warfarin in patients with AF and valvular heart disease have yet to be established.
Do direct oral anticoagulants reduce thromboembolic events and bleeding compared to warfarin in patients with atrial fibrillation and valvular heart disease?
Meta-Analysis (n=17,533)
Do direct oral anticoagulants reduce thromboembolic events and bleeding compared to warfarin in patients with atrial fibrillation and valvular heart disease?
In patients with AF and VHD, specific DOACs like dabigatran and edoxaban demonstrate favorable efficacy and safety profiles compared to warfarin, whereas rivaroxaban may increase systemic embolism risk.
Answers are grounded in this paper and cite their sources.
Supports preferring certain DOACs over warfarin in AF with VHD; extends RCT data via network comparisons of agents.
Introduction: Atrial fibrillation (AF) and valvular heart disease (VHD) are common comorbidities, increasing the risk of thromboembolic events. While warfarin has been the standard for preventing stroke in AF patients, direct oral anticoagulants (DOACs) have emerged as an effective substitute. However, their safety and efficacy in VHD patients have yet to be established. Objective: To compare the effectiveness and safety of different DOAC agents versus warfarin in patients with AF and VHD in a network meta-analysis (NMA). Methods: We conducted an online search of databases for eligible studies from inception to April 2023. For dichotomous variables, we calculated the effect size using the risk ratio (RR) and its confidence interval (CI). We conducted frequentist and pairwise meta-analyses using the random-effects model in R-studio software. Results: Seven randomized controlled trials with 17533 patients were included in the review. Analysis of 6 studies showed that dabigatran 150 mg (RR 0.59, 95% CI [0.36, 0.98]) was associated with a lower risk of stroke compared to warfarin. Edoxaban 30 mg was associated with a significantly lower risk of major bleeding (RR 0.43, 95 CI [0.23, 0.81]). Compared to warfarin, dabigatran 110 mg (RR 0.29, 95% CI [0.13, 0.68]), edoxaban 30 mg (RR 0.30, 95% CI [0.11, 0.80]), dabigatran 150 mg (RR 0.36, 95% CI [0.17, 0.77]), edoxaban 60 mg (RR 0.37, 95% CI [0.15, 0.93]), and apixaban (RR 0.40, 95% CI [0.27, 0.61]), were associated with a significantly lower risk of intracranial hemorrhage (ICH). All DOACs did not show any difference in terms of all-cause or cardiovascular mortality, except for rivaroxaban Conclusion: In patients with AF and VHD, Edoxaban 30 mg is the safest DOAC agent associated with a reduced risk of major bleeding, ICH, and GI trouble. Dabigatran 150 mg is associated with a reduced risk of stroke and ICH but with a higher risk of GI trouble. However, Rivaroxaban is associated with an increased risk of systemic embolism.
No takes yet. Share an insight, caveat, or question.
Taha et al. (2023) conducted a meta-analysis in Atrial fibrillation and valvular heart disease (n=17,533). Direct oral anticoagulants (DOACs) vs. Warfarin was evaluated on stroke (RR 0.59, 95% CI 0.36-0.98). In patients with AF and VHD, dabigatran 150 mg reduced the risk of stroke compared to warfarin (RR 0.59; 95% CI 0.36-0.98), and multiple DOACs significantly lowered the risk of intracranial hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: